BioStock Investor Meeting: Idogen presents

Idogen's newly appointed interim CEO Christina Herder took the opportunity to introduce herself and above all the company at the BioStock Investor Meeting. The company, which is developing tolerogenic cell therapies and is approaching a phase I/IIa study with the main candidate IDO8, has also begun the exercise period for warrants of series TO 5. This runs between 15 – 29 September.

See the presentation at biostock.se:

https://www.biostock.se/en/2022/09/biostock-investor-meeting-idogen-presents/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/